Immunocompetent murine models for the study of glioblastoma immunotherapy

摘要: Glioblastoma remains a lethal diagnosis with 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes modest, no small part due to tumor-induced immunosuppressive mechanisms that promote escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the response while neutralizing immunosuppression will play critical role improving treatment for glioblastoma patients. In vivo murine models glioma provide an invaluable resource achieving end, their use is essential preclinical workup novel therapeutics need be tested animal prior testing experimental therapies this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A SMA-560 (VM/Dk), 4C8 (B6D2F1), each which offer suitable platform immunotherapeutic approaches.